{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:54:04Z","timestamp":1784901244572,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>No transfusion\u2010associated cases of variant Creutzfeldt\u2013Jakob disease (vCJD) have occurred in more than 20\u2009years. Yet, many countries have maintained blood donor deferral criteria for vCJD. We developed a risk simulation model to reassess the need for vCJD\u2010related deferral criteria in Canada.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The model provides results separately for H\u00e9ma\u2010Qu\u00e9bec (HQ) and Canadian Blood Services (CBS). The model used a Monte Carlo simulation approach to estimate the risk of having a vCJD\u2010contaminated blood donation (\u2018risk of vCJD\u2019) in a simulated cohort of 10 million donors followed for up to 85\u2009years. The model assumed current deferral criteria for vCJD were lifted, which would allow new \u2018at\u2010risk\u2019 donors to give blood. The model accounted for disease prevalence, donors' travel\/immigration history, <jats:italic>PRNP<\/jats:italic> genotype at codon 129, demographics and the type of labile blood product.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the base case, the risk of vCJD was estimated at zero at both blood services. In the most pessimistic scenario, the risk of vCJD was 6.4\u2009\u00d7\u200910<jats:sup>\u22129<\/jats:sup> (i.e., 1 in 157 million donations) at HQ, or \u22641 in 77 million based on the upper bound of the 95% confidence interval (CI). At CBS, this risk was 4.8\u2009\u00d7\u200910<jats:sup>\u22128<\/jats:sup> (i.e., 1 in 21 million donations), or \u22641 in 16 million based on the upper bound of the 95% CI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>vCJD poses minimal risks to the Canadian blood supply. Current vCJD deferral criteria may, therefore, be lifted with virtually no impact on safety, while significantly expanding the donor base.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vox.13493","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:23:48Z","timestamp":1689726228000},"page":"738-745","source":"Crossref","is-referenced-by-count":2,"title":["Risk of variant <scp>Creutzfeldt<\/scp>\u2013<scp>Jakob<\/scp> disease in a simulated cohort of Canadian blood donors"],"prefix":"10.1111","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9678-5286","authenticated-orcid":false,"given":"Alexis","family":"Pozzo di Borgo","sequence":"first","affiliation":[{"name":"Medical Affairs and Innovation H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Germain","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation H\u00e9ma\u2010Qu\u00e9bec  Qu\u00e9bec Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2789","authenticated-orcid":false,"given":"Sheila F.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Epidemiology and Surveillance Canadian Blood Services  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-7117","authenticated-orcid":false,"given":"Gilles","family":"Delage","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Renaud","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-4198","authenticated-orcid":false,"given":"Antoine","family":"Lewin","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation H\u00e9ma\u2010Qu\u00e9bec  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"European Centre for Disease Prevention and Control.EU case definition. [cited 2023 Mar 7]. Available from:https:\/\/www.ecdc.europa.eu\/en\/infectious\u2010diseases\u2010public\u2010health\/variant\u2010creutzfeldt\u2010jakob\u2010disease\/eu\u2010case\u2010definition."},{"key":"e_1_2_9_3_1","unstructured":"Creutzfeldt\u2013Jakob Disease International Surveillance Network.vCJD cases worldwide. [cited 2023 Feb 2]. Available from:https:\/\/www.eurocjd.ed.ac.uk\/data_tables."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91412-9"},{"key":"e_1_2_9_5_1","first-page":"221","volume-title":"Management of health risks from environment and food\u2014policy and politics of health risk management in five countries\u2014Asbestos and BSE","author":"Webster A","year":"2010"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-20565-1_12"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12637"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03018300"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12840"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009276"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16812-8"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042019"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.3.964.bloodjournal723964"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712253372601"},{"key":"e_1_2_9_15_1","unstructured":"US Food and Drug Administration.Recommendations to reduce the possible risk of transmission of Creutzfeldt\u2013Jakob disease and variant Creutzfeldt\u2013Jakob disease by blood and blood components. [cited 2023 Feb 3]. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt."},{"key":"e_1_2_9_16_1","unstructured":"Australian Government\u2014Department of Health and Aged Care.TGA approval to change blood donation rules relating to vCJD deferral. [cited 2023 Feb 3]. Available from:https:\/\/www.tga.gov.au\/news\/news\/tga-approval-change-blood-donation-rules-relating-vcjd-deferral."},{"key":"e_1_2_9_17_1","unstructured":"Department of Health & Social Care.Risk assessment of the transmission of vCJD by blood components\u2014technical report.2019[cited 2023 Feb 3]. Available from:https:\/\/www.gov.uk\/government\/publications\/vcjd\u2010transmission\u2010by\u2010blood\u2010components\u2010risk\u2010assessment."},{"key":"e_1_2_9_18_1","unstructured":"Statistics Canada.Period of immigration by admission category and place of birth: Canada provinces and territories census metropolitan areas and census agglomerations with parts. [cited 2023 Mar 10]. Available from:https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv!recreate.action?pid=9810031701&selectedNodeIds=1D26 2D79 2D80 2D81 2D82 2D83 2D84 2D85 2D86 2D87 2D104 2D109 2D116 2D119 2D125 2D130 2D134 2D217 3D12 3D14 3D15 5D1&checkedLevels=0D1 2D5 3D2 5D1 6D1&refPeriods=20210101 20210101&dimensionLayouts=layout3 layout3 layout3 layout3 layout3 layout3 layout3 layout2&vectorDisplay=false."},{"key":"e_1_2_9_19_1","unstructured":"Statistics Canada.Deaths by age group and sex. [cited 2023 Mar 10]. Available from:https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv!recreate\u2010nonTraduit.action?pid=1310070901&selectedNodeIds=1D6&checkedLevels=0D1%2C1D1%2C1D2%2C2D2&refPeriods=20200101%2C20200101&dimensionLayouts=layout3%2Clayout3%2Clayout3%2Clayout2&vectorDisplay=false&request_locale=en."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5675"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015626"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13290"},{"key":"e_1_2_9_23_1","first-page":"4739","article-title":"Prion diseases are efficiently transmitted by blood transfusion in sheep","volume":"112","author":"Houston F","year":"2008","journal-title":"Blood J Am Soc Hematol"},{"key":"e_1_2_9_24_1","unstructured":"Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9.Analysis of the risk of transmission of variant of Creutzfeldt\u2013Jakob disease by health products and by tissues and fluids of human origin\u2014Update of findings of ad hoc group report of December 2000.2004[cited 2023 Feb 3]. Available from:https:\/\/archiveansm.integra.fr\/var\/ansm_site\/storage\/original\/application\/2906328b3b0e08c665a7c7b0e5c42020.pdf."},{"key":"e_1_2_9_25_1","unstructured":"UK Health Security Agency.Summary results of the third national survey of abnormal prion prevalence in archived appendix specimens. Health Protection Report.2016[cited 2023 Feb 6]. Available from:https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/546883\/hpr2616.pdf."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00488-7"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03637.x"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.13493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T02:51:31Z","timestamp":1714963891000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.13493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/vox.13493"],"URL":"https:\/\/doi.org\/10.1111\/vox.13493","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}